ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Heterogeneity among the vaccine hesitant…

Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data

Vaccine·August 19Open Access
ImmunologyConfirms priorCOVID-19Vaccine HesitancyCross-Sectional Survey (Secondary Analysis)VaccineMixed

Summary

View source

What was studied

This secondary analysis of the CEAL Common Survey 2 (November 2020–November 2022) examined demographic factors associated with COVID-19 vaccine hesitancy, trust in physicians and institutions (e.g., CDC, FDA), and reasons for vaccine refusal among 13,802 U.S. residents across 21 sites.

Key findings

Over 12% of respondents were unvaccinated; Non-Hispanic Black participants had the lowest vaccination rate (81.78%) vs. Non-Hispanic White (91.80%). Educational gradient was steep: 20.78% of those with a high school education were unvaccinated vs. 6.18% with a graduate degree. Adults 55+ were less likely to be unvaccinated than younger participants. While <5% distrusted their doctors, >40% distrusted the FDA to ensure a safe pediatric vaccine. Racial and educational differences existed in specific reasons for non-vaccination (e.g., needle aversion, community disapproval).

Study limitations

Secondary analysis limits causal inference. Survey respondents may not be nationally representative despite multi-site recruitment. Full text was inaccessible, so granular methodological details (e.g., sampling strategy, response rates) could not be verified.

Clinical implications

Tailored vaccine outreach is needed by subgroup: address community-level norms and needle aversion in lower-education and minority communities, and prioritize rebuilding FDA trust for pediatric vaccine uptake. A single-message campaign is unlikely to reach all hesitant groups equally.

Caveats

  • Full publisher page text was inaccessible (bot-check wall); summary is based solely on the abstract. Methodological details such as sampling strategy, survey response rates, and adjusted odds ratios could not be verified.
  • Study design tag reflects a cross-sectional secondary analysis, which limits causal interpretation — clinicians should note associations are not causal.
  • The DOI and publication date (2026) are unusual; confirmed as provided in source metadata.

Related Questions

Explore related topics

What are the most effective strategies to reduce COVID-19 vaccine hesitancy in Black and Hispanic communities?How does trust in the FDA affect pediatric vaccine acceptance among parents?What interventions address vaccine hesitancy related to needle fear and community norms?

Publication Details

Year
2026
Journal
Vaccine
Sample Size
n=13,802
Source
View article
Keep scrolling
More content below.
Up Next